Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Rocket Pharmaceuticals due to significant losses suffered by investors following misleading statements regarding the safety of its clinical trial for RP-A501 [2][4]. Group 1: Company Overview - Rocket Pharmaceuticals, Inc. is a publicly traded company on NASDAQ under the ticker RCKT [2]. - The company has faced scrutiny for its handling of clinical trial protocols and communication with investors [4]. Group 2: Legal Actions and Investigations - A federal securities class action has been filed against Rocket Pharmaceuticals, with a deadline of August 11, 2025, for investors to seek the role of lead plaintiff [2][7]. - Faruqi & Faruqi encourages investors who suffered losses exceeding $50,000 between February 27, 2025, and May 26, 2025, to discuss their legal options [1]. Group 3: Clinical Trial Issues - The complaint alleges that Rocket Pharmaceuticals provided overly positive statements while concealing material adverse facts about the safety of RP-A501 and the clinical trial protocol [4]. - On May 27, 2025, the FDA placed a clinical hold on the RP-A501 Phase 2 pivotal study after a patient suffered a Serious Adverse Event, including death, which was not disclosed to investors prior to the incident [5]. Group 4: Stock Price Impact - Following the announcement of the clinical hold, Rocket's stock price plummeted from $6.27 per share on May 23, 2025, to $2.33 per share on May 27, 2025, marking a decline of approximately 37% in just one trading day [6].

Core Viewpoint - The article discusses a class action lawsuit against Sarepta Therapeutics, alleging violations of the Securities Exchange Act of 1934 due to misleading statements regarding the safety and efficacy of its gene therapy product, ELEVIDYS, for Duchenne muscular dystrophy [1][3]. Company Overview - Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on developing therapies for Duchenne muscular dystrophy, including the gene therapy ELEVIDYS [2]. Allegations of the Lawsuit - The lawsuit claims that Sarepta and its executives made false or misleading statements about ELEVIDYS, including significant safety risks, failure to detect severe side effects in trials, and the potential for halting recruitment and dosing due to adverse events [3]. - Specific incidents cited include: - On March 18, 2025, a patient treated with ELEVIDYS suffered acute liver failure leading to death, causing Sarepta's stock to drop over 27% [4]. - On April 4, 2025, Sarepta disclosed that EU authorities requested a review of the death, leading to a further stock decline of over 7% [5]. - On June 15, 2025, a second patient died from acute liver failure, prompting Sarepta to suspend shipments and pause dosing, resulting in a stock price drop of over 42% [6]. - On June 24, 2025, the FDA announced an investigation into the risk of acute liver failure associated with ELEVIDYS, causing an additional stock decline of over 8% [7]. Legal Process - Investors who purchased Sarepta securities during the class period can seek appointment as lead plaintiff in the lawsuit, which allows them to act on behalf of other class members [8].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Red Cat Holdings, Inc. due to allegations of misleading statements regarding the company's production capacity and contract values, which have led to significant investor losses [2][4][12]. Group 1: Company Overview - Red Cat Holdings, Inc. (NASDAQ: RCAT) is involved in the production of small unmanned aerial systems (sUAS) for military applications, specifically under the U.S. Army's Short Range Reconnaissance Program [5][11]. - The company announced in March 2022 that it was selected to compete in the U.S. Army's SRR Program, which is aimed at providing portable sUAS to Army platoons [5]. Group 2: Allegations and Misleading Statements - The complaint against Red Cat alleges that the company overstated the production capacity of its Salt Lake City facility and the overall value of the SRR Contract, leading to materially false and misleading public statements [4][6]. - During a conference call on July 27, 2023, Red Cat revealed that the Salt Lake City facility could only produce 100 drones per month, contrary to earlier claims of thousands, and that the facility was still under construction [7]. - Following these disclosures, Red Cat's stock price fell by 8.93% to close at $1.02 per share on July 28, 2023 [8]. Group 3: Financial Performance and Stock Impact - In the first quarter of fiscal year 2025, Red Cat reported losses per share of $0.17, missing consensus estimates by $0.09, and revenue of $2.8 million, missing estimates by $1.07 million [9]. - After announcing a pause in manufacturing due to retooling the Salt Lake City facility, Red Cat's stock price dropped by 25.32% over two trading sessions, closing at $2.36 per share on September 25, 2024 [10]. - A report published by Kerrisdale Capital on January 16, 2025, alleged that the SRR Contract was worth only $20 million to $25 million, significantly lower than previously stated, leading to a further stock price decline of 21.54% [12][13]. Group 4: Legal Proceedings - Investors who suffered losses exceeding $50,000 in Red Cat between March 18, 2022, and January 15, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal options [1][2]. - The deadline to seek the role of lead plaintiff in the federal securities class action against Red Cat is July 21, 2025 [2].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against PepGen Inc. due to allegations of violations of federal securities laws related to misleading statements about the effectiveness and safety of its drug PGN-EDO51, leading to significant stock price declines and investor losses [2][4]. Group 1: Legal Investigation and Claims - Faruqi & Faruqi is encouraging investors who suffered losses exceeding $50,000 in PepGen between March 7, 2024, and March 3, 2025, to discuss their legal options [1]. - The firm reminds investors of the August 11, 2025, deadline to seek the role of lead plaintiff in a federal securities class action against PepGen [2]. - The complaint alleges that PepGen and its executives made false and misleading statements regarding the effectiveness and safety of PGN-EDO51 and the CONNECT2 study, which was deemed deficient for FDA approval [4]. Group 2: Clinical Study Results and Stock Performance - On July 30, 2024, PepGen reported "positive clinical data" from the CONNECT1 study, but analysts noted that the results were below expectations, leading to a stock price drop of $5.55 per share, or 32.69%, closing at $11.43 [5][6]. - Following a clinical hold notice from the FDA on December 16, 2024, regarding the CONNECT2 study, PepGen's stock fell by $0.17 per share, or 3.63%, to close at $4.51 [7][8]. - On January 29, 2025, PepGen disclosed safety concerns in the CONNECT1 study, resulting in a stock price decline of $0.40 per share, or 21.74%, closing at $1.44 [9][10]. - The company announced a voluntary pause of the CONNECT2 study on March 4, 2025, leading to a further stock drop of $0.53 per share, or 18.86%, closing at $2.28 [10]. - On May 28, 2025, PepGen disclosed that PGN-EDO51 did not achieve target dystrophin levels and decided to discontinue its DMD programs [11].

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, primarily related to misleading statements and the promotion of illegitimate products, which led to a significant drop in stock price following the termination of a partnership with Novo Nordisk [1][2]. Company Overview - Hims & Hers is a telehealth company that offers prescription medications, over-the-counter medications, and personal care products [2]. - The company announced a collaboration with Novo Nordisk on April 29, 2025, to sell a bundled offering of Wegovy® [2]. Legal Allegations - The class action lawsuit alleges that Hims & Hers engaged in deceptive practices by promoting and selling illegitimate versions of Wegovy®, which jeopardized patient safety [2]. - Following the allegations, Novo Nordisk terminated its partnership with Hims & Hers on June 23, 2025, citing the deceptive practices as the reason [2]. - The lawsuit claims that the stock price of Hims & Hers fell by more than 34% after the announcement of the partnership termination [2]. Class Action Process - Investors who purchased Hims & Hers securities during the specified class period can seek to be appointed as lead plaintiff in the lawsuit [3]. - The lead plaintiff represents the interests of all class members and can select a law firm to litigate the case [3]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [4]. - The firm has a strong track record in obtaining significant recoveries in securities class action cases, including the largest recovery in history of $7.2 billion in the Enron case [4].

Core Viewpoint - Rosen Law Firm has announced the filing of a class action lawsuit on behalf of purchasers of common stock of Hims & Hers Health, Inc. during the specified Class Period, indicating potential legal issues surrounding the company's disclosures and partnerships [1][5]. Group 1: Lawsuit Details - The class action lawsuit pertains to common stock purchases of Hims & Hers Health, Inc. between April 29, 2025, and June 23, 2025 [1]. - The lawsuit claims that Hims made false and misleading statements regarding its partnership with Novo Nordisk A/S, particularly about the availability of the weight-loss drug Wegovy for Hims subscribers [5]. - Specific allegations include that Hims failed to disclose the nature of its collaboration with Novo, which was supposed to ensure continued access to Wegovy, and that positive statements were made about the partnership that misled investors [5]. Group 2: Participation Information - Investors who purchased Hims common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by August 25, 2025, to represent the class in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements, recovering hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in representing investor rights [4].

Core Viewpoint - Hayward Holdings, Inc. is facing legal scrutiny regarding allegations of misleading investors about sales practices and inventory levels, with a securities fraud lawsuit moving forward against the company and its executives [2][3]. Group 1: Legal Investigation - Schubert Jonckheer & Kolbe LLP is investigating potential legal claims related to Hayward Holdings, urging current shareholders to reach out for more information [1]. - The investigation focuses on whether Hayward's officers and directors engaged in wrongdoing concerning the alleged misleading sales practices [3]. Group 2: Securities Fraud Lawsuit - A U.S. District Court judge has allowed key claims in a securities fraud lawsuit against Hayward Holdings to proceed, which alleges that the company inflated sales figures through "channel stuffing" and pushed excess inventory into the distribution pipeline [2]. - The lawsuit claims that these practices resulted in an undisclosed inventory glut, negatively impacting future sales and leading to a decline in Hayward's stock price when the truth was revealed, causing significant losses for investors [2].

NEW YORK, June 26, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Strategy Incorporated (NASDAQ: MSTR).Shareholders who purchased shares of MSTR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/strategy-incorporated-loss-submission-form/?id=154282&from=4CLASS PERIOD: April 30, ...

NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit. Investors have until July 14, 2 ...

NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Fortrea Holdings Inc. (NASDAQ: FTRE) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Fortrea you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/fortrea-holdings-inc-class-action-lawsuit. Investors have until August 1, 2025, to ask th ...